Anticonvulsants and Chromatin-Genes Expression: A Systems Biology Investigation

Area of Science:

• Developmental Biology
• Epigenetics
• Genomics

Background:

• Embryofetal development requires precise epigenetic regulation.
• Anticonvulsant medications are known to impact epigenetics-related genes.
• The precise mechanisms linking anticonvulsant-induced epigenetic changes to fetal syndromes remain unclear.

Purpose of the Study:

• To investigate the effects of valproic acid, carbamazepine, and phenytoin on epigenetics-related gene expression.
• To identify key genes and pathways involved in anticonvulsant-induced embryofetal developmental issues.
• To discover potential biomarkers for drug-induced fetal syndromes.

Main Methods:

• Analysis of publicly available genomic data from murine and human embryonic stem cells exposed to anticonvulsants.
• Differential gene expression (DGE) analysis to identify individual gene changes.
• Weighted gene co-expression network analysis (WGCNA) to uncover gene network alterations, focusing on epigenetics.

Main Results:

• While few individual epigenetics genes showed differential expression, WGCNA revealed significant enrichment of chromatin remodeling genes across all three drug exposures.
• Specific gene sets associated with Fetal Valproate Syndrome (e.g., SMARCA2, SMARCA4) and Fetal Hydantoin Syndrome (e.g., PAX6, NEUROD1, TSHZ1) were identified.
• The study highlights the impact of these anticonvulsants on critical developmental pathways.

Conclusions:

• Anticonvulsant exposure significantly impacts chromatin remodeling pathways during early development.
• Candidate genes identified may serve as biomarkers for predicting and potentially preventing drug-induced congenital anomalies.
• Studying stem cells under drug exposure provides valuable insights into developmental toxicity mechanisms.